Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial
NCT ID: NCT01525810
Last Updated: 2015-03-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
218 participants
OBSERVATIONAL
2012-03-31
2014-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
NCT01616524
Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection
NCT01257204
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
NCT01598090
Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C
NCT01754974
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
NCT01795911
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Subjects treated with Peginterferon Lambda-1a (BMS-914143)
Subjects who participated in a clinical trial in which Peginterferon Lambda-1a (BMS-914143) was administered for the treatment of chronic hepatitis C
Peginterferon Lambda-1a (BMS-914143)
Observational study - No Intervention \[subjects were previously treated with Peginterferon Lambda-1a (BMS-914143)\]
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Peginterferon Lambda-1a (BMS-914143)
Observational study - No Intervention \[subjects were previously treated with Peginterferon Lambda-1a (BMS-914143)\]
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Scripps Clinic
La Jolla, California, United States
Yale University School Of Medicine
New Haven, Connecticut, United States
Orlando Immunology Center
Orlando, Florida, United States
Gastrointestinal Specialists Of Georgia
Marietta, Georgia, United States
The Queen'S Medical Center
Honolulu, Hawaii, United States
Henry Ford Health System
Detroit, Michigan, United States
Mayo Clinic
Rochester, Minnesota, United States
Duke University Medical Center
Durham, North Carolina, United States
Consultants For Clinical Research
Cincinnati, Ohio, United States
Texas Clinical Research Institute
Arlington, Texas, United States
St. Luke'S Episcopal Hospital - Baylor College Of Medicine
Houston, Texas, United States
University Of Texas Health Science Center At Houston
Houston, Texas, United States
Va Medical Center (151)
Houston, Texas, United States
Texas Liver Institute
San Antonio, Texas, United States
Clinical Research Centers Of America
Murray, Utah, United States
Metropolitan Research
Annandale, Virginia, United States
Virginia Mason Medical Center
Seattle, Washington, United States
Local Institution
Buenos Aires, Buenos Aires, Argentina
Local Institution
Buenos Aires, Buenos Aires, Argentina
Local Institution
Buenos Aires, Buenos Aires, Argentina
Local Institution
Mar del Plata, Buenos Aires, Argentina
Local Institution
Rosario, Santa Fe Province, Argentina
Local Institution
Buenos Aires, , Argentina
Local Institution
Camperdown, New South Wales, Australia
Local Institution
Darlinghurst, New South Wales, Australia
Local Institution
Randwick, New South Wales, Australia
Local Institution
Sydney, New South Wales, Australia
Local Institution
Westmead, New South Wales, Australia
Local Institution
Greenslopes, Queensland, Australia
Local Institution
Herston, Queensland, Australia
Local Institution
Woolloongabba, Queensland, Australia
Local Institution
Adelaide, South Australia, Australia
Local Institution
Fitzroy, Victoria, Australia
Local Institution
Heidelberg, Victoria, Australia
Local Institution
Melbourne, Victoria, Australia
Local Institution
Parkville, Victoria, Australia
Local Institution
Vienna, , Austria
Local Institution
Leuven, , Belgium
Local Institution
Liège, , Belgium
Toronto Digestive Disease Associates, Inc.
Vaughan, Ontario, Canada
Local Institution
Hus, , Finland
Local Institution
Clichy, , France
Local Institution
Créteil, , France
Local Institution
Montpellier, , France
Local Institution
Nice, , France
Local Institution
Paris, , France
Local Institution
Paris, , France
Local Institution
Pessac, , France
Local Institution
Hamburg, , Germany
Local Institution
Heidelberg, , Germany
Local Institution
Athens, , Greece
Local Institution
Thessaloniki, , Greece
Local Institution
Cisanello (pisa), , Italy
Local Institution
Florence, , Italy
Local Institution
Milan, , Italy
Local Institution
Milan, , Italy
Local Institution
Napoli, , Italy
Local Institution
Novara, , Italy
Local Institution
Viale Del Policlinico, 155, , Italy
Local Institution
Guadalajara, Jalisco, Mexico
Local Institution
Amsterdam, , Netherlands
Local Institution
Leiden, , Netherlands
Local Institution
Auckland, , New Zealand
Local Institution
Bialystok, , Poland
Local Institution
Krakow, , Poland
Local Institution
Wroclaw, , Poland
Local Institution
San Juan, , Puerto Rico
Local Institution
Bucharest, , Romania
Local Institution
Bucharest, , Romania
Local Institution
Iași, , Romania
Local Institution
Timișoara, , Romania
Local Institution
Busan, , South Korea
Local Institution
Barcelona, , Spain
Local Institution
Barcelona, , Spain
Local Institution
Valencia, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
BMS clinical trial educational resource
Investigator Inquiry form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011-005293-31
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
AI452-016
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.